New York – October 15, 2024 – Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering (IPO). Upstream Bio offered 17,250,000 shares priced at $17 per share, which includes the full exercise of the underwriters’ option to purchase 2,250,000 additional shares. Upstream Bio’s common stock began trading on the Nasdaq Global Select Market on October 11, 2024, under the ticker symbol UPB. J.P. Morgan, TD Cowen, Piper Sandler and William Blair acted as joint book-running managers for the offering.
Partners Kristin VanderPas, David Peinsipp, Denny Won and Charlie Kim led the Cooley team that advised the underwriters.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.